Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 99 EP750 | DOI: 10.1530/endoabs.99.EP750

National Medical Institute of the Ministry of the Interior and Administration in Warsaw, Warszawa, Poland


Background: The alterations in collagen synthesis and connective tissue structure that occur in Ehlers–Danlos syndrome translate to an increased risk of bone mass loss and development of osteopenia and osteoporosis, which may be evaluated with bone turnover biomarkers. Some subtypes of Ehlers–Danlos syndrome are associated with structural alterations in the extracellular matrix glycoprotein tenascin-X. The purpose of this study was to assess the relationship between tenascin-X and both bone turnover markers and bone mineral density (BMD) in patients with Ehlers–Danlos syndrome.

Material and methods: This study involved a prospective evaluation of 30 female patients, aged 20–53 years, with hypermobile or classical Ehlers–Danlos syndrome. All patients underwent tests of their tenascin-X levels, calcium and phosphorus metabolism parameters, and BMD scans of the femoral neck and lumbar spine.

Results: The study showed no significant correlation between tenascin-X levels on one hand and femoral neck BMD (rs 0.13, P=0.49), lumbar spine BMD (rs 0.17, P=0.36), alkaline phosphatase levels (rs 0.18, P=0.33), beta-crossLaps levels (rs 0.11, P=0.56), or osteocalcin levels (rs -0.08, P=0.66). Univariate logistic regression showed no statistically significant effect of tenascin-X levels on the development of osteoporosis (OR 0.48, 95% CI 0–1.32, P=0.99).

Conclusions: Tenascin-X does not show significant correlation with either bone turnover markers or BMD in females with Ehlers–Danlos syndrome.

Volume 99

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.